Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population

NCT05580458 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

225

Enrollment

NIH

Sponsor class

Conditions

Herpes Zoster

Interventions

BIOLOGICAL: Shingrix

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)